Cervicon-DIM, vaginal suppositories 100 mg 25 pcs

Treatment of cervical dysplasia (cervical intraepithelial neoplasia) (regardless of the results of detection of papillomavirus infection by PCR).

Indications

Treatment of dysplasia (cervical intraepithelial neoplasia) of the cervix (regardless of the results of detection of human papillomavirus infection by PCR).

Pharmacological effect

ATX code:
L01XX
Pharmacological properties

Special instructions

When treating vaginal infections, the drug should not be used during menstruation; it is advisable to start treatment after menstruation. During the treatment period, it is recommended to abstain from sexual intercourse.

Active ingredient

Diindolylmethane

Composition

One suppository contains:

Contraindications

Individual intolerance to any of the components of the drug.
The period of pregnancy and breastfeeding.
Children under 18 years of age.

Side Effects

The drug is usually well tolerated by patients.

In some cases, the following, usually reversible, undesirable effects may occur. The adverse events presented below are listed depending on the anatomical and physiological classification and frequency of occurrence. The frequency of side effects is classified by WHO and has gradations: very often (≥1/10), often (≥1/100 and <1/10), infrequently (≥1/1000 and <1/100), rarely (≥1/10000 and <1/1000), very rarely (<1/10000), not established.

Adverse events
often (≥1/100 and <1/10) uncommon (≥1/1000 and <1/100) Immune system disorders hives, itching
Heart disorders

shortening of atrioventricular conduction
Vascular disorders

increased blood pressure
Gastrointestinal disorders

diarrhea
Skin and subcutaneous tissue disorders

petechial rash on the skin; slower hair growth on the head and body
Disorders of the genital organs and breast
discomfort, burning, itching in the vagina; leucorrhoea and flaky discharge from the genital tract
dryness in the vagina during sexual intercourse; delayed menstruation
Laboratory and instrumental data
increased activity of aspartate aminotransferase and alanine aminotransferase in blood plasma; thrombocytopenia and increased erythrocyte sedimentation rate; bacteriuria, leukocyturia, proteinuria, ketonuria
decrease in plasma creatinine concentration; leukocytosis in a cervical smear; vaginal dysbiosis; signs of myocardial hypoxia on the electrocardiogram

If any of the undesirable reactions indicated in the instructions appear or worsen, or if you notice any other undesirable reactions not listed in the instructions, tell your doctor.

Interaction

Not studied.

Overdose

Overdose symptoms are unknown.

Storage conditions

In a place protected from light at a temperature of 2 °C to 8 °C.

Shelf life

2 years.

Manufacturer

Altfarm, Russia